Pfizer Settlement Means New Oversight; Does It Mean A New Marketing Plan?
Executive Summary
The government may be hoping the third time's the charm as it enters into a new corporate integrity agreement with Pfizer
You may also be interested in...
Pfizer False Claims Act Ruling Keeps High Evidentiary Standards, Limits Employee Protections
Appeals court rules that aggregate data of government expenditures are not a substitute evidence of actual false claims and that FCA does protect whistleblowers who just report regulatory violations.
Healthiness Of Actors In DTC Spots Returns As Issue As FDA Cites Aricept Ads
Pfizer, which co-markets the Alzheimer's treatment with Eisai, could feel the biggest impact of the notice of violation due to its settlement with state attorneys general.
Lessons From The Pfizer Off-Label Settlement: Compliance Programs Not Enough To Demonstrate Integrity, DOJ Says
A lesson of Pfizer's $2.3 billion corporate integrity settlement with the Department of Justice is that good integrity policies are meaningless without employee adherence, according to government attorneys